News About: Pharm. Industry
Aggressive stimulus measures for pharmaceutical industry needed
Rhee Jang-han, new chief-director of the Korea Pharmaceutical Manufacturers Association, said that the KPMA will concentrate its efforts to revamp the current reimbursement price system to a level that is sufficient t...
Smaller package of drug should be preferred, KPA and Wholesalers say
Business sources say that to cope with the rapidly increasing volume of drug inventories in pharmacy, a smaller package of drug should be supplied as a fundamental measure.
1) Korea Pharmaceutical Association
T...
KPMA gets four new vice-chief directors
The Korea Pharmaceutical Manufacturers Association held the second board of directors meeting and elected four new vice-chief directors including Huh Il-seob, vice-chairman of Korea Green Cross; Yang Heung-joon, presi...
Few wholesalers to procure Glivec stocks.
A growing number of patients are looking for Glivec as the KFDA extended its indication ranges and therefore drug wholesalers should get enough stocks, but very few secured its stocks.
A drug wholesaler located in...
Organon to conduct multinational studies in patients with breast cancer
In the large, multinational (25 countries), multicenter (150 hospitals) clinical trials, Organon intends to assess the effect and safety of Livial (tibolone) in patients with the history of breast cancer who have comp...
Factive's potential value worths 244.3 billion won
As the Advisory Committee of the US FDA consisting of outside experts recommended the approval of LG Life Sciences' novel fluoroquinolone antibiotic Factive through hearings on March 4, the FDA will be likely to appro...
Korea's local vaccines export in 2002 topped $45 million
The Korea Food and Drug Administration said that Korea exported $45 million worth of its locally produced vaccines exported in 2002 to many countries (Mexcio, Brazil, Argentina, Vietnam, Pakistan, Sri Lanka, and Afric...
Government urged to grease R&D investment wheels
Business sources say that to better enhance R&D capability in the domestic pharmaceutical industry, the current reimbursement price criteria needs to be readjusted in a manner such that new R&D fund including the intr...
Industry complaining government's subsidy cut off for new drug R&D.
The pharmaceutical industry sensitively concerned about the government budgeting plans for the new drug R&D subsidy to skip. The MOHW budget amounting to the total 89,200 million won for the first half of 2003 did not...
Antidepressant market getting overheated
With the incessant new antidepressants launch, many foreign-invested firms have expanded their presence in the domestic antidepressants market, according to business sources.
The market scale for antidepressants la...
